The Intracellular level of FLASH decreases during apoptosis. by Song Chen (69646)

C2GnT1 gene knockdown decreases C2-O-sLe^X glycoproteins and C2GnT1 activity. by Catherine A. St. Hill (357388)

“…Note the absence of a detected C2GnT1 protein 50 kDa band. (D) We observed a 30–40% decrease in reactivity with CHO-131 mAb by flow cytometry for LS174T and HepG2 cells that contained C2GnT1 shRNA. …”

Tranilast decreases RANKL-induced ROS level. by Tien Van Phan (583324)

Cortactin knockdown results in decreased FA turnover. by Alok Tomar (139282)

Chemical Inhibition of eEF1A-1 Peptide Elongation Activity Decreases Palmitate-Induced Cell Death. by Alexandra M. Stoianov (759321)

Diabetic kidney shows decreased klotho expression. by Jeong Suk Kang (7359572)

“…<p>(a) Representative images of the kidney from normal and diabetic biopsies showing the decreased klotho expression in diabetic podocytes by IHC. …”

Nicotine-induced Tumor Growth is decreased by BEL. by Lindsay E. Calderon (332344)

Piceatannol decreases renal fibrosis in the UUO kidney. by Sin Young Choi (3370778)

Ear stimulation targets used of taVNS or staVNS. by Duyan Geng (12072181)

Subjects:

Fig 4 - by Duyan Geng (12072181)

Subjects:

Fig 6 - by Duyan Geng (12072181)

Subjects:

Fig 5 - by Duyan Geng (12072181)

Subjects:

Microglia-conditioned medium decreases NPC viability. by Johanna Mäkelä (223358)

Data_Sheet_1_Marathon Running Increases Synthesis and Decreases Catabolism of Joint Cartilage Type II Collagen Accompanied by High-Energy Demands and an Inflamatory Reaction.PDF by José A. Hernández-Hermoso (11545663)

“…Mean sC2C levels (220.83 ± 39.50 ng/ml) decreased post-race (188.67 ± 38.52 ng/ml) (p = 0.002). …”

In the null model the event rate does not decrease as a function of the inverse of time. by Thomas O. Richardson (251876)

A2EN supernatants do not decrease cell-free HIV viability. by Lyndsey R. Buckner (843006)

AGE-modification of laminin leads to a decrease in Kir4.1 function. by Kayla Thompson (4885036)

T198A/G substitution markedly decrease p27 protein stability. by Monica Schiappacassi (227672)

Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study by Asita Wongprikorn (2837378)

“…At 12 weeks of treatment with pitavastatin compared to placebo; mean [95% confidence interval (CI)] total cholesterol (TC) was 207 (187.3, 226.8) mg/dL vs 246.3 (226.5, 266) mg/dL (<i>p</i> <0.001); mean (95% CI) triglyceride (TG) was 351.3 (193.2, 509.4) mg/dL vs 279.1 (121, 437.2) mg/dL (<i>p</i> = 0.269); mean (95% CI) high density lipoprotein (HDL) was 45.3 (40.4, 50.2) mg/dL vs 44.2 (39.3, 49.1) mg/dL (<i>p</i> = 0.354); and mean (95% CI) low density lipoprotein (LDL) was 113.2 (100.4, 126) mg/dL vs 145.6 (132.8, 158.4) mg/dL (<i>p</i> <0.001). …”

Decreased α-cell mass and early structural alterations of the exocrine pancreas in patients with type 1 diabetes: An analysis based on the nPOD repository by Fidéline Bonnet-Serrano (4782546)

“…Results were expressed as mean ±SD.</p><p>Results</p><p>An automated quantification method was set up using the R software and was validated by quantification of β-cell mass, a well characterized parameter. β-cell mass was 29.6±112 mg in patients and 628 ±717 mg in controls (p<0.0001). α-cell mass was 181±176 mg in patients and 349 ±241mg in controls (p<0.0001). …”